Skip to main content
Premium Trial:

Request an Annual Quote

So Long, Princeton (and All Those Others)

Now that Pfizer's acquisition of Wyeth is complete, the cuts are coming -- this week, the pharma announced that it would shut down six of its 20 research facilities (with some question marks hanging over others). "Pfizer didn't say how many R&D jobs it would cut or how much it hoped to save from the shutdowns," according to this news analysis story from the Wall Street Journal.

Among the sites being closed: Princeton, NJ; Chazy, Rouses Point, and Plattsburgh, NY; Gosport, Slough, and Taplow in the UK; and Sanford and Research Triangle Park, NC. WSJ adds that Pfizer "is also planning to move work from its Collegeville, Pa.; Pearl River, N.Y., and St. Louis sites to other locations."

The Associated Press has a helpful list of the closed and remaining sites, as well as what scientific activities are centered at each. And if you really want to delve into this, Pharmaconduct has put together a spreadsheet listing Pfizer's facilities going back through several of its last acquisitions and detailing the status of each.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.